Biotech Buzz: Market Flops and Oil Jitters!

Biotech Bullshit Sequel: Futures Fizzle, Oil Jiggles on Iran Jizz-Jab!

Premarket prick-tease—Dow futures -0.4% ~46,000[1][2], S&P -0.2% ~6,600[1], Nasdaq -0.15% ~24,300[2] as WTI crude dongs at ~$96 amid Trump-Iran truce teases and supply spook revival—energy erections twitch, biotechs blast cumshots again.[1] [2] ARTL ass-rocket, ONCO orgasm, SLND slapdown—bulls balls-deep, bears bitch bankruptcy. First-principles prick-poke incoming.[3]


1) Artelo Biosciences (ARTL): “GLP-1 Glaucoma Glory Hole” vs “Reverse-Split Rug-Pull”

Why it’s loud
ARTL detonating +149% pre to ~$8 biotech boner supreme—third-party funded glaucoma study on ART27.13 companion to GLP-1s, eye-candy expansion into $16B market.[3] [4]

Bull case (endocannabinoid eye-fuck euphoria)
ART27.13 peripheral CB1 blocker squirts IOP drop potential sans side effects, fully funded Vanderbilt collab = no cash burn, cancer pipeline bonus for multi-bagger moon to $20+.[5]

Bear case (serial splitter scam-shit)
Fresh 3:1 reverse split reeks dilution desperation, microcap meme volatility vomit, history of hype-farts without FDA cum.[6]

My take, first principles (CB1 moat vs money pit)
Boil the biology: Selective peripheral modulation = real edge in glaucoma stack if data dongs, but funding facade hides burn—oil irrelevant flyer. Scoop $7.50-7.80, $10/$12 calls study spurt—puts $6.50 split stink. Risk: Trial tease flop.[4]


2) Onconetix (ONCO): “Nasdaq Lifeline Load-Up” vs “Merger Dump Dilution”

Why it’s loud
ONCO surging +82% pre to ~$5.80 oncology overachiever—Nasdaq panel grants compliance extension, $12.9M Series D/warrants financing juices runway despite Ocuvex merger nix.[7] [8]

Bull case (prostate punch revival)
Favorable hearing = listing lifeline, cash infusion funds men's health pivot (Realbotix sexbot tie-in?), oncology pipeline prick for $10+ squeeze.[9]

Bear case (offering overdose obituary)
Merger termination = red flag flop, private placement dilution dick-slap incoming, penny pump prone to rug.[10]

My take, first principles (financing fix vs fuckery)
Core the cash: Extension buys trial time, but warrants = shareholder shaft if exercised. Biotech bingo. Buy $5.20-5.50, $7/$9 calls lifeline lift—puts $4.50 dump dive. Risk: More offerings.[3]


3) Southland Holdings (SLND): “$118M Project Prick” vs “$89M Lawsuit Limp”

Why it’s loud
SLND cratering -29% pre to ~$1.15 infra implosion—$118M data center/data projects NTP glow, but annual report coughs $89M legal liability bomb on convention fiasco.[11] [12]

Bull case (backlog bonanza build)
$2B backlog bulge with infra spend orgasm, recent wins signal rebound to $5+ on execution erect.[13]

Bear case (liability lawsuit laceration)
Revenue reversal + $89M hit guts profits, execution risks in recession = bankruptcy balls-off.[14]

My take, first principles (backlog ballast vs liability leak)
Strip the structure: Fat backlog moats if lawsuits settle soft, but legal drag = margin murder. Oil indirect via infra. Grab $1.10-1.20, $1.80/$2.20 calls project pop—puts $0.90 liability limp. Risk: More reversals.[5]


Tape-Side Tactics (biotech blast or infra bust?)

  • ARTL: $7.50-7.80 glaucoma glory; $10C/$12C spreads, P$6.50 split shit. [3]
  • ONCO: $5.20-5.50 lifeline load; $7C/$9C, P$4.50 dilution dump. [7]
  • SLND: $1.10-1.20 backlog balls; $1.80C/$2.20C, P$0.90 lawsuit lash. [11]

Iran itch or itch-scratch? Biotech hump or dump. DYOR, balls to the wall.